Design, Synthesis, and Activity Evaluation of Novel N-benzyl Deoxynojirimycin Derivatives for Use as α-Glucosidase Inhibitors

To obtain α-glucosidase inhibitors with high activity, 19 NB-DNJDs (N-benzyl-deoxynojirimycin derivatives) were designed and synthesized. The results indicated that the 19 NB-DNJDs displayed different inhibitory activities towards α-glucosidase in vitro. Compound 18a (1-(4-hydroxy-3-methoxybenzyl)-2-(hydroxymethyl) piperidine-3,4,5-triol) showed the highest activity, with an IC50 value of 0.207 ± 0.11 mM, followed by 18b (1-(3-bromo-4-hydroxy-5-methoxybenzyl)-2-(hydroxymethyl) piperidine-3,4,5-triol, IC50: 0.276 ± 0.13 mM). Both IC50 values of 18a and 18b were significantly lower than that of acarbose (IC50: 0.353 ± 0.09 mM). According to the structure-activity analysis, substitution of the benzyl and bromine groups on the benzene ring decreased the inhibition activity, while methoxy and hydroxyl group substitution increased the activity, especially with the hydroxyl group substitution. Molecular docking results showed that three hydrogen bonds were formed between compound 18a and amino acids in the active site of α-glucosidase. Additionally, an arene–arene interaction was also modelled between the phenyl ring of compound 18a and Arg 315. The three hydrogen bonds and the arene–arene interaction resulted in a low binding energy (−5.8 kcal/mol) and gave 18a a higher inhibition activity. Consequently, compound 18a is a promising candidate as a new α-glucosidase inhibitor for the treatment of type Ⅱ diabetes.

[1]  S. Withers,et al.  Rapid Discovery of Potent and Selective Glycosidase-Inhibiting De Novo Peptides. , 2017, Cell chemical biology.

[2]  N. Ismail,et al.  Synthesis, molecular docking studies of hybrid benzimidazole as α-glucosidase inhibitor. , 2017, Bioorganic chemistry.

[3]  Martin D. Witte,et al.  Mechanism-based inhibitors of glycosidases: design and applications. , 2014, Advances in carbohydrate chemistry and biochemistry.

[4]  Chaohong Guo,et al.  Discovery of novel bromophenol 3,4-dibromo-5-(2-bromo-3,4-dihydroxy-6-(isobutoxymethyl)benzyl)benzene-1,2-diol as protein tyrosine phosphatase 1B inhibitor and its anti-diabetic properties in C57BL/KsJ-db/db mice. , 2013, European journal of medicinal chemistry.

[5]  B. Jiang,et al.  Design, Synthesis, and Biological Evaluation of Bromophenol Derivatives as Protein Tyrosine Phosphatase 1B Inhibitors , 2012, Archiv der Pharmazie.

[6]  E. Şahin,et al.  Total Synthesis of the Biologically Active, Naturally Occurring 3,4‐Dibromo‐5‐[2‐bromo‐3,4‐dihydroxy‐6‐(methoxymethyl)benzyl]benzene‐1,2‐diol and Regioselective O‐Demethylation of Aryl Methyl Ethers , 2010 .

[7]  H. Kurihara,et al.  Alpha-glucosidase inhibitory activity of bromophenol purified from the red alga Polyopes lancifolia. , 2010, Journal of food science.

[8]  R. Dwek,et al.  Improved cellular inhibitors for glycoprotein processing α-glucosidases: biological characterisation of alkyl- and arylalkyl-N-substituted deoxynojirimycins , 2009 .

[9]  P. Huleatt,et al.  Expedient Routes to Valuable Bromo-5,6-dimethoxyindole Building Blocks. , 2008 .

[10]  P. Huleatt,et al.  Expedient routes to valuable bromo-5,6-dimethoxyindole building blocks , 2008 .

[11]  H. Overkleeft,et al.  Large-Scale Synthesis of the Glucosylceramide Synthase Inhibitor N-[5-(Adamantan-1-yl-methoxy)-pentyl]-1-deoxynojirimycin , 2008 .

[12]  P. Murphy,et al.  Hybrid angiogenesis inhibitors: synthesis and biological evaluation of bifunctional compounds based on 1-deoxynojirimycin and aryl-1,2,3-triazoles. , 2008, Bioorganic & medicinal chemistry letters.

[13]  K. Nakagawa,et al.  Occurrence of orally administered mulberry 1-deoxynojirimycin in rat plasma. , 2007, Journal of agricultural and food chemistry.

[14]  H. Overkleeft,et al.  Development of adamantan-1-yl-methoxy-functionalized 1-deoxynojirimycin derivatives as selective inhibitors of glucosylceramide metabolism in man. , 2007, The Journal of organic chemistry.

[15]  Ivone Carvalho,et al.  α- and β-Glucosidase inhibitors: chemical structure and biological activity , 2006 .

[16]  P. Compain,et al.  α-1-C-Alkyl-1-deoxynojirimycin Derivatives as Potent and Selective Inhibitors of Intestinal Isomaltase: Remarkable Effect of the Alkyl Chain Length on Glycosidase Inhibitory Profile. , 2005 .

[17]  P. Compain,et al.  Alpha-1-C-alkyl-1-deoxynojirimycin derivatives as potent and selective inhibitors of intestinal isomaltase: remarkable effect of the alkyl chain length on glycosidase inhibitory profile. , 2004, Bioorganic & medicinal chemistry letters.

[18]  R. Dwek,et al.  Cellular effects of deoxynojirimycin analogues: uptake, retention and inhibition of glycosphingolipid biosynthesis. , 2004, The Biochemical journal.

[19]  Jay S Skyler,et al.  Diabetes mellitus: pathogenesis and treatment strategies. , 2004, Journal of medicinal chemistry.

[20]  Xiaoping Zhou,et al.  Specific inhibition effects of N-pentafluorobenzyl-1-deoxynojirimycin on human CD4+ T cells. , 2004, Bioorganic & Medicinal Chemistry Letters.

[21]  H. Ploegh,et al.  Distribution and Elimination of the Glycosidase Inhibitors 1-Deoxymannojirimycin and N-Methyl-1-Deoxynojirimycin in the Rat in Vivo , 1992, Pharmaceutical Research.

[22]  R. Dwek,et al.  Membrane disruption and cytotoxicity of hydrophobic N-alkylated imino sugars is independent of the inhibition of protein and lipid glycosylation. , 2003, The Biochemical journal.

[23]  Y. Takenaka,et al.  Phenyl ethers from cultured lichen mycobionts of Graphis scripta var. serpentina and G. rikuzensis. , 2003, Chemical & pharmaceutical bulletin.

[24]  J. Klinman,et al.  De novo design and utilization of photolabile caged substrates as probes of hydrogen tunneling with horse liver alcohol dehydrogenase at sub-zero temperatures: a cautionary note. , 2003, Bioorganic chemistry.

[25]  L. Pickering,et al.  Preparation, biochemical characterization and biological properties of radiolabelled N-alkylated deoxynojirimycins. , 2002, The Biochemical journal.

[26]  B. Ganem,et al.  Synthesis of glycolipid analogues that disrupt binding of HIV-1 gp120 to galactosylceramide. , 2000, Bioorganic & medicinal chemistry letters.

[27]  R. Dwek,et al.  Molecular requirements of imino sugars for the selective control of N-linked glycosylation and glycosphingolipid biosynthesis , 2000 .

[28]  Rosângela S. C. Lopes,et al.  Synthesis of 1-Deoxynojirimycin and N-Butyl-1-deoxynojirimycin. , 1999 .

[29]  Mitani,et al.  Two new bromophenols from the red alga odonthalia corymbifera , 1999, Journal of natural products.

[30]  H. Kurihara,et al.  Inhibitory Potencies of Bromophenols from Rhodomelaceae algae against α-Glucosidase Activity , 1999 .

[31]  B. Junge,et al.  Chemistry and Structure-Activity Relationships of Glucosidase Inhibitors , 1996 .

[32]  M. Kiso,et al.  Synthetic and structural studies of α-sialyl-(2 → 6) and α-sialyl-(2 → 3) 1-deoxynojirimycin derivatives potentially useful for biomedical applications☆ , 1995 .